Sage Therapeutics Inc (NASDAQ: SAGE) kicked off on Tuesday, up 3.23% from the previous trading day, before settling in for the closing price of $7.44. Over the past 52 weeks, SAGE has traded in a range of $4.62-$14.97.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 3403.60% over the last five years. While this was happening, its average annual earnings per share was recorded 48.38%. With a float of $54.08 million, this company’s outstanding shares have now reached $61.36 million.
The firm has a total of 353 workers. Let’s measure their productivity. In terms of profitability, gross margin is 77.1%, operating margin of -1046.9%, and the pretax margin is -971.48%.
Sage Therapeutics Inc (SAGE) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Sage Therapeutics Inc is 12.03%, while institutional ownership is 82.56%. The most recent insider transaction that took place on Dec 10 ’24, was worth 41,441.
Sage Therapeutics Inc (SAGE) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.92 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 48.38% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 38.75% during the next five years compared to 13.20% growth over the previous five years of trading.
Sage Therapeutics Inc (NASDAQ: SAGE) Trading Performance Indicators
Take a look at Sage Therapeutics Inc’s (SAGE) current performance indicators. Last quarter, stock had a quick ratio of 7.42. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.45.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -6.60, a number that is poised to hit -0.98 in the next quarter and is forecasted to reach -2.52 in one year’s time.
Technical Analysis of Sage Therapeutics Inc (SAGE)
Analysing the last 5-days average volume posted by the [Sage Therapeutics Inc, SAGE], we can find that recorded value of 0.77 million was lower than the volume posted last year of 1.76 million. As of the previous 9 days, the stock’s Stochastic %D was 89.97%. Additionally, its Average True Range was 0.36.
During the past 100 days, Sage Therapeutics Inc’s (SAGE) raw stochastic average was set at 70.80%, which indicates a significant decrease from 84.20% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 61.86% in the past 14 days, which was lower than the 68.56% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.50, while its 200-day Moving Average is $7.46. Now, the first resistance to watch is $7.80. This is followed by the second major resistance level at $7.91. The third major resistance level sits at $8.10. If the price goes on to break the first support level at $7.50, it is likely to go to the next support level at $7.31. Now, if the price goes above the second support level, the third support stands at $7.20.
Sage Therapeutics Inc (NASDAQ: SAGE) Key Stats
The company with the Market Capitalisation of 472.18 million has total of 61,481K Shares Outstanding. Its annual sales at the moment are 41,240 K in contrast with the sum of -400,670 K annual income. Company’s last quarter sales were recorded 12,820 K and last quarter income was -95,780 K.
